The degree of variability in the use of cytomegalovirus prevention strategies, and choice of antiviral regimens among liver transplant centers has not been previously investigated.
|Valganciclovir is the most commonly used agent for antiviral prophylaxis|
|American Journal of Transplantation|
Dr Levitsky and colleagues from Illinois, USA sent an electronic survey on current cytomegalovirus prevention strategies to all US and Canadian liver transplant centers.
A total of 53% centers completed the survey.
Most use cytomegalovirus polymerase chain reaction for screening or diagnosis.
The research team observed that prophylaxis was the most common prevention strategy for all donor/recipient subtypes.
The researchers found that prophylaxis was usually given for 3 months after liver transplantation with valganciclovir, the most frequently used agent.
In the small percentage of centers utilizing the preemptive approach, monitoring for cytomegalovirus with polymerase chain reaction for 3 months was the most frequently used.
In addition, valganciclovir was most frequently used for treatment of detectable cytomegalovirus viremia.
Dr Levitskys' team concluded, "The majority of liver transplant centers utilize cytomegalovirus prophylaxis over other strategies."
"Valganciclovir is the most commonly used agent for both antiviral prophylaxis, and treatment of cytomegalovirus viremia in the preemptive approach."